Because Europe deserved clinically pure at-home NAD+ — built on clinical science, delivered cold-chain, and designed to work.
Why NAD+ Access in Europe Has Been Difficult — Until Now
For the past decade, the longevity research community — led by scientists like David Sinclair at Harvard, supported by clinicians worldwide — has built a compelling case for NAD+ restoration as one of the most evidence-grounded interventions in aging biology.
Clinics in the United States, the United Kingdom, and Australia began offering IV NAD+ therapy. Biohackers and athletes started experimenting with at-home wellness kits. Beneath-the-skin longevity pens became the standard approach for people who had done the research and did not want to spend €400 per clinic session.
In Europe, this was largely inaccessible.
Regulatory frameworks made import difficult. No EU-native brand had built a clinically pure solution. The products that did exist were either UK-based post-Brexit (no clean EU supply chain) or research-use-only compounds from peptide suppliers with no clinical protocol attached.
We saw the gap clearly. The science was there. The demand was there. The EU had the clinical infrastructure to do this properly. What was missing was a brand willing to build it right — with EU certification, cold-chain logistics, a scientific advisor on record, and a protocol grounded in the actual literature.
That is what NADPure is. Learn more about the science behind NAD+ and CD38 decline.
The biology does not care about your postcode. We built the at-home alternative because IV clinics at €500 per session are not a protocol — they are a luxury.
Dr. Ivan Manolov
Scientific Advisor, NADPure
MD, Cardiologist — Preventive & Sports Cardiology
Vital Heart Cardiology Centre, Plovdiv
The NADPure protocol was developed in collaboration with Dr. Ivan Manolov.
What Makes NADPure Clinically Pure
Honest Science
We cite our sources. We acknowledge what the research does not yet prove. We do not claim that NAD+ will extend your lifespan, reverse all aging, or cure any condition. We say what the evidence supports and nothing more. In a category full of overclaiming, we consider honesty a competitive advantage.
Access Over Exclusivity
IV NAD+ therapy in a European clinic costs €250–€500 per session. At the recommended frequency of two to three sessions per week, that is a monthly cost of €2,000–€6,000. That is not a protocol — that is a luxury. We built the at-home alternative because the biology does not care about your postcode.
Respect for Complexity
Cellular biology is not simple. The CD38 mechanism is not a marketing story — it is a documented biochemical pathway that took decades to characterise. We explain it. We do not flatten it into a headline. The people who need this protocol are intelligent enough to understand why it works.
Your Protocol Awaits
